Article
Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status.
BMC cancer - 11 Apr 2015
Chong Dawn Q, Toh Xin Y, Ho Ivy A W, Sia Kian C, Newman Jennifer P, Yulyana Yulyana, Ng Wai-Hoe, Lai Siang H, Ho Mac M F, Dinesh Nivedh, Tham Chee K, Lam Paula Y P
Abstract excerpt
BACKGROUND: The treatment of glioblastoma multiforme (GBM) is an unmet clinical need. The 5-year survival rate of patients with GBM is less than 3%. Temozolomide (TMZ) remains the standard first-line treatment regimen for gliomas despite the fact that more than 90% of recurrent gliomas do not respond to TMZ after repeated exposure. We have also independently shown that many of the Asian-derived glioma cell lines...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.